Skip to contentV
Vsee Health, Inc.
V
VSEEWVsee Health, Inc. Q2 2024 · 10-Q
Revenue$1.71M$1.71M+34.6% vs Q2 2023 Net Income-$634.12K-$634.12KN/M vs Q2 2023 EPS Diluted-$0.12-$0.12N/M vs Q2 2023 Gross Profit$776,996−2.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vsee Health, Inc. · CIK 1864531 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,173,500N/M Free Cash Flowderived-$3,210,273— Margins · derivedGross margin45.4%−17.3 pt vs Q2 2023
Operating margin-54.5%−0.2 pt vs Q2 2023
Net margin-37.0%+2.5 pt vs Q2 2023
ended Jun 30, 2024 · filed Sep 23, 2024 · 85 d after period end